Example collocations logo

Vaccine in sentence

824 examples of Vaccine in a sentence

Yet efforts to communicate this to the public have been met with skepticism from some critics, who argue that the vaccine gives young girls tacit consent to engage in sexual activity, ultimately leading to an increase in promiscuity.
Whether such attitudes and misinformation account for poor vaccine coverage in places like France and the US is still not known.
It may simply be that some parents or girls mistakenly believe that one shot of the HPV vaccine is enough to provide protection, or that some socially disadvantaged girls lack sufficient access to in-school vaccination services.
Or perhaps the cost of the vaccine is a barrier in some of these countries.
In the US, for example, the G-8 country for which we currently have the most data, infection rates have halved in the six years since the vaccine was first introduced.
As a result, millions of parents do not have their children vaccinated, and hundreds of children become ill, with many more affected, sometimes fatally, by the disease than would have suffered adverse effects from the vaccine.
The good news is that some progress is being made, with several vaccine clinical trials already underway.
As soon as a vaccine or treatment is deemed suitable for implementation, it must be made available in large quantities, to be administered quickly to citizens at no cost to them.
As several health ministers pointed out in Addis Ababa, high vaccine prices force poor countries’ governments to make tough choices about which deadly diseases they can afford to prevent.
While Africa can and should do more to improve vaccination, the global community also has a responsibility to make a concerted effort to bring down vaccine costs.
The recently announced reduction in the price of pneumococcal vaccine is a step in the right direction, but it is not enough.
The world has known about the deadly nature of the Ebola virus since 1976; but, because its victims were poor, pharmaceutical companies had no incentive to develop a vaccine.
But now it is too late for that, and scientists are rushing to find both a vaccine and an effective treatment for Ebola.
The standard way to judge the efficacy of a vaccine is to conduct a trial in which those who could benefit are randomly assigned to two groups, one of which receives the potentially beneficial vaccine, while the other receives a substance with no active ingredients, known as a placebo.
To avoid possible confounding factors, such as greater risk-taking by those who know they have been vaccinated, or the desire of those conducting the trial to show that the vaccine works, the study is “double blind”: Neither the subjects nor those administering the trial and collecting the data know who got the vaccine and who got the placebo.
Yet if a promising vaccine is available – and if safety trials in healthy human volunteers who are not at risk of infection demonstrate that it does no harm – to deny it to those who are tending to the sick and dying, at great risk to their own health, seems unethical.
At a recent World Health Organization meeting in Geneva, Ripley Ballou, the head of GlaxoSmithKline’s program to develop a vaccine, argued that a randomized controlled trial comparing a potential Ebola vaccine with a vaccine that protects against another virus would be the most ethical way to assess efficacy.
It now takes around $300 - $500 million to develop a new vaccine, for example, a malaria vaccine.
For example, the WHO and the rich-country governments could promise to purchase an effective malaria vaccine in order to distribute it (below cost) in Africa, thereby guaranteeing the drug companies that they will have a market for a new vaccine if these companies spend the time and money to develop one.
Indeed, it has been calculated that the work being done to expand vaccine coverage in developing countries by my organization, the GAVI Alliance, should yield an 18% return on investment by 2020.
With 80% of the world’s poorest children now getting access to routine immunization – meaning three shots of a diphtheria-tetanus-pertussis-containing vaccine – we already have a health platform upon which to build UHC, even in the most challenging of countries.
(Although there is no widely available vaccine for malaria, three countries are set to take part in a pilot immunization program starting in 2018, and some mosquito-borne diseases – such as yellow fever, Japanese encephalitis, and dengue – are vaccine-preventable.)
Another innovation is a vaccine called AGS-v, developed by the London-based pharmaceutical company SEEK to provide broad protection against a range of mosquito-borne diseases.
The vaccine is designed to trigger an immune response to mosquito saliva, thereby preventing infection from whatever virus the saliva contains.
Phase I clinical trials of the vaccine, sponsored and funded by the National Institute of Allergy and Infectious Diseases, began in February.
Morally, this is no different from permitting the construction of an unsafe dam or knowingly administering a contaminated vaccine.
An infection such as the coronavirus is currently countered with a vaccine tailored to block it.
Efforts to eradicate leprosy earned the fifth spot on my list, while vaccine advances in general were sixth.
Highlights included a new typhoid vaccine, shown to improve protection for infants and young children, and a new shingles vaccine.
Clinical trials for an HIV vaccine started at the end of 2017, while doctors in South Africa reported curing a young boy of the disease after he received treatments as an infant.
BackNext